CX-157 (KP 157) is a novel monoamine oxidase-A (MAO-A) inhibitor for the study of depression-like neurological disorders and cancer.

Hydroxyamine hydrochloride(Hydroxylammonium chloride) is a selective and potent monoamine oxidase (MAO) inhibitor with inhibitory effects on platelet aggregation.Hydroxyamine hydrochloridee is an intermediate in organic synthesis and can be used to synthesize other active compounds.

MAO-B-IN-9 is a monoamine oxidase B MAO-B inhibitor (IC50: 0.18 μM) that crosses the blood-brain barrier with potency, selectivity and time-dependence. MAO-B-IN-9 has neuroprotective effects against Aβ1-42-induced neuronal cell death, which may be related to the anti-aggregation effect of Aβ1-42.

PSB-1434 is a selective and competitive monoamine oxidase B inhibitor.

PSB-1491 is a selective and competitive monoamine oxidase B inhibitor with IC50 of 0.386 nM, >25000-fold selective versus MAO-A.

MAO-B-IN-1 is a monoamine oxidase B inhibitor and can be used for the research of neurological diseases.

Harmane (Loturine) is a bio-active β-Carboline and monoamine oxidase inhibitor found in coffee and tobacco smoke.

PF-9601N showed high potency and selectivity as a MAO-BI (monoamine oxidase type B inhibitor) and also demonstrated remarkable neuroprotective properties in several in vivo and cellular models of PD.

Methylene Blue (Basic Blue 9) hydrate functions as an inhibitor of guanylyl cyclase (sGC), monoamine oxidase A (MAO-A), and NO synthase (NOS). This compound, known for its vasopressor activity, is widely utilized as a dye in various medical procedures. It operates via the nitric oxide synthase/guanylate cyclase signaling pathway to diminish prepulse inhibition and possesses the capacity to cross the blood-brain barrier. Methylene Blue hydrate acts as a REDOX cycling compound and inhibits Tau protein aggregation. Moreover, it is effective in reducing cerebral edema, damping microglial activation, and alleviating neuroinflammation, demonstrating its multifaceted therapeutic potential [1] [2] [3].

Eprobemide (LIS 630) is a non-competitive reversible inhibitor of monoamine oxidase A (MAO-A).

Tranylcypromine (SKF 385), a potent monoamine oxidase (MAO) inhibitor [1], is used in medicinal applications.

WAY-620147 is a derivative of N-(2-morpholinoethyl)nicotinamide, which is able to inhibit Monoamine Oxidase.WAY-620147 has an IC50 value of 26 μM for MAO-A and 55 μM for MAO-B, and can be used for the study of neurological diseases.

(S)-Salsolidine, a chemical compound, functions as a weak inhibitor of monoamine oxidase (MAO), exhibiting an inhibition constant (K i ) of 63 μM. R enantiomer demonstrating a greater efficacy than (S)-Salsolidine, boasting a K i value of 26 μM compared to the S form.

Cudraflavone B has anti-proliferative activity, mouse brain monoamine oxidase (MAO) inhibitory effects, apoptotic actions in human gastric carcinoma cells and mouse melanoma cells, and hepatoprotective activity. It may be a lead for the development of a potential candidate for human oral squamous cell carcinoma cells.

MAO-B-IN-27 (Compound 12c), a monoamine oxidase B (MAO-B) inhibitor, exhibits a potent and selective inhibitory effect on hMAO-B, with an IC50 value of 8.9 nM, and is utilized in Parkinson's disease (PD) research [1].

Bifemelane hydrochloride is a MAO inhibitor

Pargyline hydrochloride (Pargylamine hydrochloride) is an irreversible monoamine oxidase(MAO) inhibitor with antihypertensive properties.

Moclobemide-d4 is a deuterated compound of Moclobemide. Moclobemide has a CAS number of 71320-77-9. Moclobemide is a reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.

Ladostigil hemitartrate (TV-3326) is a compound that acts as a dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO). It has IC50 values of 37.1 μM for MAO-B and 31.8 μM for AChE. In addition, Ladostigil hemitartrate possesses neuroprotective, antioxidant, and anti-inflammatory properties. It is commonly used in research relating to depression and Alzheimer's disease.

Tranylcypromine hemisulfate (Tranylcypromine Sulfate) is an inhibitor of monoamine oxidase (MAO) and lysine-specific demethylase 1 (LSD1) with a rapid onset of activity.

MAO-IN-3 (Compound 5), a reversible and competitive monoamine oxidase (MAO) inhibitor with inhibition constants (K i) of 0.6 μM for MAO A and 0.2 μM for MAO B, effectively suppresses LN-229 glioblastoma cell proliferation, as denoted by an inhibitory concentration (IC50) of 0.8 μM. This compound holds potential application in cancer research [1].

ETAP, a dual inhibitor of both monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B), exhibits antidepressant-like effects and is utilized in the research of major depressive disorder [1].

SL-25.1188 is a monoamine oxidase B (MAO-B) inhibitor. SL-25.1188 is characterized by reversible binding, high brain uptake, and very slow plasma metabolism in vivo.

AChE/MAO-IN-1 is a potent inhibitor of human acetylcholinesterase (AChE), monoamine oxidase A (MAO-A), and monoamine oxidase B (MAO-B), demonstrating inhibitory concentrations (IC50) of 0.0248 μM, 0.0409 μM, and 0.1108 μM against AChE, MAO-A, and MAO-B, respectively.

Mebanazine, a potent monoamine oxidase (MAO) inhibitor, is utilized in depression research.

FTEAA, a 4-styrylpiperidine inhibitor, effectively inhibits monoamine oxidase (MAO), displaying IC50 values of 0.52 μM (MAO-A) and 1.02 μM (MAO-B). Its potent activity suggests potential application in research related to cardiovascular, neurological, and oncological disorders.

Fluoroclorgyline is a specific inhibitor of monoamine oxidase A (MAO-A).

Monoamine oxidase/Aromatase-IN-1 (compound 2q) is a potent dual inhibitor of monoamine oxidase (MAO) and aromatase, with IC50 values of 39 nM and 31 nM for MAO-B and aromatase, respectively. It holds significant potential for research in neurological disorders and breast cancer [1].

Pivalylbenzhydrazine (Pivhydrazine) is a potent monoamine oxidase (MAO) inhibitor. Pivalylbenzhydrazine decreases the growth of cartilage in normal rats. Pivalylbenzhydrazine can be used in research of depression [1].

MAO-B-IN-11, also known as Compound 8c, is a highly potent inhibitor of monoamine oxidase B (MAO-B), with an IC50 value of 1.3 μM. Additionally, MAO-B-IN-11 exhibits neuroprotective properties [1].

Methyl citrate, obtained from Opuntia ficus-indica var. saboten Makino fruits, serves as a potent Monoamine oxidase B (MAO-B) inhibitor with an IC50 value of 0.23 mM.

MAO-B-IN-25 (compound 92) is a selective inhibitor of monoamine oxidase B (MAO-B), exhibiting inhibitory half-maximal inhibitory concentrations (IC50) of 240 nM for MAO-B and 0.5 nM for MAO-A [1].

MAO A/HDAC-IN-1 is an effective monoamine oxidase A (MAO A) and HDAC dual inhibitor, which can be used for glioma research.

Phenoxypropazine, a potent monoamine oxidase (MAO) inhibitor, is utilized in depression research.

AChE/BChE/MAO-B-IN-3, an indan-1-one derivative, serves as a potent inhibitor of human monoamine oxidase B (MAO-B) with an IC50 of 0.0359 μM, demonstrating significant inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50 values of 0.0473 μM and 0.0782 μM, respectively. Exhibiting notable antioxidant activity, AChE/BChE/MAO-B-IN-3 holds considerable promise for Alzheimer's disease (AD) research.

AChE/BChE/MAO-B-IN-4, an indan-1-one derivative, serves as a potent inhibitor for both monoamine oxidase B (MAO-B) and acetylcholinesterase/butyrylcholinesterase (AChE/BChE) enzymes. It exhibits a strong inhibitory effect on human MAO-B with an IC50 of 0.0393 μM, and demonstrates significant potency against human AChE and BChE enzymes with IC50 values of 0.0458 μM and 0.075 μM, respectively. Additionally, this compound displays notable antioxidant properties and the ability to prevent β-amyloid plaque aggregation, marking its potential utility in Alzheimer's disease (AD) research.

CAY10680 is a dopamine-sparing, benzothiazinone compound that selectively inhibits both MAO-B activity (IC50 = 34.9 nM in human) and adenosine A2A receptors (Ki = 39.5 nM in human). It demonstrates significantly less potent inhibitory values for other adenosine receptor subtypes (Kis > 1 μM) and MAO-A (IC50 ≥ 10 μM). At 1-20 μM, CAY10680 has been shown to abolish cAMP accumulation in CHO cells transfected with adenosine A2A receptors. In the central nervous system adenosine A2A receptor expression is localized to dopamine-innervated areas where heteromeric complexes are formed with dopamine D2 receptors. Because inhibition of adenosine A2A receptors has been shown to enhance D2 receptor function, the blockade of adenosine A2A receptors has emerged as a potential treatment for Parkinson's disease. An additional strategy in the treatment of Parkinson's disease has been to block the activity of monoamine oxidase B (MAO-B), the enzyme involved in dopamine catabolism.

Monoamine Oxidase B inhibitor 2 is a potent, reversible, orally active and selective inhibitor of monoamine oxidase B (MAO-B) (IC50 = 1.33 nM) which can across the blood-brain barrier (BBB). Monoamine Oxidase B inhibitor 2 shows antioxidant and anti-neuroinflammatory activities which can be used in the study of Parkinson’s disease [1].

MAO-B-IN-17 is a selective and potent monoamine oxidase B (MAO-B) inhibitor (IC50: 5.08 μM) for the study of central nervous system disorders like Parkinson's.

MAO-B-IN-16 is a selective inhibitor of monoamine oxidase B (MAO-B ) (IC 50 = 1.55 μM) that can be used in the central nervous disorders study, for example, parkinson's disease [1].

Rosiridin (6'-O-Deacetylrosiridoside C) has cardioprotective activity.

RS 8359 is a reversible inhibitor of monoamine oxidase A (MAO-A) with a selectivity ratio of about 2200 for the A:B enzyme types. RS 8359 has antidepressant activity.

MAO-B-IN-3 is a reversible, selective inhibitor of monoamine oxidase B (MAO-B) with an IC50 of 96 nM and demonstrates affinity for the 5-HT6 receptor with a Ki of 696 nM, making it suitable for Alzheimer's disease research [1].

MAO-B-IN-4 (Compound 26) is a reversible monoamine oxidase B (MAO-B) inhibitor with potent in vitro activity, characterized by an IC50 value of 9 nM. This orally active compound exhibits favorable metabolic stability, a satisfactory safety profile, and effective brain permeability. Demonstrating antidepressant effects in rodent models, MAO-B-IN-4 is suitable for research into Alzheimer's disease [1].

IHC3 is a competitive and reversible monoamine oxidase B (MAO-B) inhibitor with an IC50 of 1.672 μM, which targets Cys172 within the enzyme's active site. It is utilized in the study of neurological diseases [1].

MAO-B-IN-14 (Compound 9) is a potent and selective inhibitor of monoamine oxidase-B (MAO-B) with an IC 50 of 0.95 μM and a Ki of 0.55 μM for human MAO-B.

Moclobemide-d8 is a deuterated compound of Moclobemide. Moclobemide has a CAS number of 71320-77-9. Moclobemide is a reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.

MRX-I, a monoamine oxidase-A (MAO-A) Inhibitor, is used potentially for the treatment of acute bacterial skin.

Budipine is a non-dopaminergic antiparkinsonian drug. The primary action of budipine is an indirect dopaminergic effect as shown by facilitation of dopamine (DA) release, inhibition of monoamine oxidase type B (MAO-B) and of DA (re) up-take and stimulatio

Mebanazine oxalate is a potent monoamine oxidase (MAO) inhibitor. Mebanazine oxalate can be used in research of depression.